Ikarian Capital’s 89bio ETNB Stock Holding History

Ikarian Capital’s Portfolio ETNB Stock Details ETNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,504	Closed	-$5.41M	–	149
2023 Q3	$5.41M	Buy	+3,504	New	+$58.8K	0.65%	48

Other funds holding ETNB

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ikarian Capital's ETNB Position: Q2 2025 in Review

Ikarian Capital sold out of 89bio (ETNB) in Q2 2025, closing a stake of 100,000 shares — an estimated $727K sold.

Ikarian Capital first reported a position in ETNB in Q3 2020 and held it in 5 quarters. The position peaked at $8.73M in Q3 2020. 184 funds tracked by Wall St. Rank hold ETNB as of Q2 2025.

Ikarian Capital reported no remaining 89bio position as of Q2 2025 after selling out during the quarter.
Ikarian Capital sold 100,000 89bio shares in Q2 2025, an estimated $727K.
Ikarian Capital first reported a position in 89bio in Q3 2020 and held it in 5 quarters.
Ikarian Capital's 89bio position peaked at $8.73M in Q3 2020.
184 funds tracked by Wall St. Rank held 89bio as of Q2 2025.

Based on Ikarian Capital's 13F filing for Q2 2025, filed 14 Aug 2025.